Abstract

Abstract Background: Lung malignancy is a leading cause of cancer related morbidity and mortality worldwide. The three main subtypes of Non-small cell lung cancer (NSCLC) are adenocarcinoma, squamous cell lung cancers (SqCLCs) and large-cell carcinoma. Flavopiridol is a flavone that inhibits several cyclindependent kinases and exhibits potent growthinhibitory activity, apoptosis and G1 phase arrest in a number of human tumor cell lines. The present study focused on the effect of flavopiridol in cell stabilization, cell adhesion, junctional complex and epithelial to mesenchymal transition (EMT) in mouse lung squamous cell carcinoma cell. Methods: Cell viability and proliferation of untreated controls and flavopiridol treated cells were determined by using the WST-1 assay. SqCLCs and M. dunni mouse skin fibroblast cells (MSF) cells immunofluorescence analyses were performed for the evaluation of Hsp90β, e-cadherin and occludin. The percentages of CD133+/CD44+ cells in the flavopiridol treated cells when compared with the control untreated cells by flow cytometric analysis. Results: Flow cytometric analysis showed that the percentages of CD133+ and CD44+ cells did not show significant changes when compared to the untreated cells. Hsp90b expression which is significantly available in SqCLCs was considered as important its significant reduction by following flavopiridol application and also flavopiridol caused the significant increase the E-cadherin expression but there was no significant effect on the occludin expression. SqCLCs cells are uniformly highly sensitive to flavopiridol induced cytotoxicity during prolonged 72 h exposure to clinically achievable concentrations of this drug. Conclusions: These observations may have translational implications for the use of flavopiridol in the treatment of SqCLCs.

Highlights

  • Lung malignancy is a leading cause of cancer related morbidity and mortality worldwide

  • We investigated the effect of flavopiridol on the expression of two putative stem cell markers, plasma membrane-associated glycoproteins CD133 and CD44 in squamous cell lung cancers (SqCLCs) cell line

  • The percentages of Cd133+/Cd44+ cells in the flavopiridol treated cells when compared with the control untreated cells

Read more

Summary

Introduction

Lung malignancy is a leading cause of cancer related morbidity and mortality worldwide. The three main subtypes of NSCLC are adenocarcinoma, SqCLCs and large-cell carcinoma. More than 55% of lung carcinomas harbor at least one genetic alteration, most of them being histologic subtype specific. This fact suggests that inhibition of cdks involved in the control of cell cycle is not the only mechanism of action. Inhibition of cdk’s with additional functions (i.e. involved in the control of transcription or function of proteins that do not control cell cycle) may contribute to the antitumoral effect. Direct and indirect inhibition of receptor activation (EGFR) and: or a direct inhibition of kinases (pp Src, PKC, Erk-1) involved in the signal transduction pathway could play a role in the antiproliferative activity of flavopiridol [4]. The three main subtypes of Non-small cell lung cancer (NSCLC) are adenocarcinoma, squamous cell lung cancers (SqCLCs) and large-cell carcinoma. The present study focused on the effect of flavopiridol in cell stabilization, cell adhesion, junctional complex and epithelial to mesenchymal transition (EMT) in mouse lung squamous cell carcinoma cell

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call